GlucoTrack
GCTK
10 hedge funds and large institutions have $104K invested in GlucoTrack in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
25% more funds holding
Funds holding: 8 → 10 (+2)
8.79% more ownership
Funds ownership: 7.02% → 15.81% (+8.8%)
58% less capital invested
Capital invested by funds: $248K → $104K (-$144K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$99.8K |
| 2 |
HF
HRT Financial
New York
|
+$86.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$108 |
GCTK Hedge Fund Activity: Q1 2026 in Review
10 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q1 2026, worth a combined $104K — down 58% from $248K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GCTK positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $99.8K. The largest seller was Bank of America, exiting entirely with an estimated $108 sold.
- 10 institutional investors held GlucoTrack (GCTK) as of Q1 2026, up from 8 in Q4 2025.
- Funds reported $104K of GlucoTrack stock for Q1 2026, down 58% quarter-over-quarter.
- 3 funds opened new GlucoTrack positions in Q1 2026 and 1 closed out, a net change of +2 holders.
- The largest GlucoTrack buyer in Q1 2026 was Geode Capital Management, an estimated $99.8K added.
- The largest GlucoTrack seller in Q1 2026 was Bank of America, an estimated $108 sold.
Based on aggregated 13F filings for Q1 2026.